文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胸膜间皮瘤的分子见解:揭示致病机制与治疗机遇

Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities.

作者信息

Zahiu Teodora, Mihu Carmen Mihaela, Bosca Bianca A, Mărginean Mariana, Mocan Lavinia Patricia, Ștefan Roxana-Adelina, Suflețel Rada Teodora, Mihu Carina, Melincovici Carmen Stanca

机构信息

Radiology and Imaging Department, County Emergency Hospital, 400006 Cluj-Napoca, Romania.

Department of Morpho-Functional Sciences, Discipline of Histology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

出版信息

Diagnostics (Basel). 2025 May 24;15(11):1323. doi: 10.3390/diagnostics15111323.


DOI:10.3390/diagnostics15111323
PMID:40506895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12154783/
Abstract

Pleural mesothelioma (PM) is a rare disease, which is going to be a global medical concern in the 21st century, because of its aggressiveness, late diagnosis, and insufficient therapies. This review seeks to enhance the comprehension of medical professionals regarding the risk factors and environmental influences that contribute to the development of the disease, as well as its underlying mechanisms. In addition, we aim to provide a schematic yet thorough overview of diagnostic techniques in PM, emphasizing the significance of the immunohistochemical markers BAP1 and MTAP, with the latter serving as an almost ideal surrogate for the gold-standard diagnostic approach, FISH p16/CDKN2A deletion. The scientific world is grappling with BAP1, MTAP, and the tumour inflammatory microenvironment, because they are the key for personalized treatments and palliative care in this disease. Considering that the survival rate for patients with PM seldom surpasses five years, every moment is significant. Therefore, our article also highlights recent advancements in clinical assessments related to prognostic scoring and treatment options. PM is a complex disease, with gradual progression over decades, which requires further investigation covering the prevention, mutations, diagnosis and treatment.

摘要

胸膜间皮瘤(PM)是一种罕见疾病,鉴于其侵袭性、诊断延迟和治疗手段不足,它将成为21世纪全球医学关注的问题。本综述旨在增进医学专业人员对导致该疾病发生的风险因素和环境影响及其潜在机制的理解。此外,我们旨在对PM的诊断技术提供一个简要而全面的概述,强调免疫组化标志物BAP1和MTAP的重要性,其中后者几乎可作为金标准诊断方法——FISH检测p16/CDKN2A缺失的理想替代方法。科学界正在努力研究BAP1、MTAP和肿瘤炎性微环境,因为它们是该疾病个性化治疗和姑息治疗的关键。鉴于PM患者的生存率很少超过五年,每一刻都至关重要。因此,我们的文章还重点介绍了与预后评分和治疗选择相关的临床评估的最新进展。PM是一种复杂疾病,病程长达数十年且呈渐进性发展,需要在预防、突变、诊断和治疗等方面开展进一步研究。

相似文献

[1]
Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities.

Diagnostics (Basel). 2025-5-24

[2]
The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.

Pathology. 2024-8

[3]
Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.

Ann Diagn Pathol. 2022-10

[4]
Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.

Diagn Cytopathol. 2024-4

[5]
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series.

Pathol Res Pract. 2024-7

[6]
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.

Lung Cancer. 2016-12-23

[7]
A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.

Arch Pathol Lab Med. 2023-3-1

[8]
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.

Hum Pathol. 2017-2

[9]
Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.

Mod Pathol. 2022-10

[10]
Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.

Lung Cancer. 2019-2-27

本文引用的文献

[1]
Air pollution and survival in patients with malignant mesothelioma and asbestos-related lung cancer: a follow-up study of 1591 patients in South Korea.

Environ Health. 2024-6-10

[2]
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.

JAMA Oncol. 2024-4-1

[3]
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.

Clin Cancer Res. 2024-3-1

[4]
Asbestos and Iron.

Int J Mol Sci. 2023-8-3

[5]
Sarcomatoid Mesothelioma with Bland Histologic Features: A Potential Pitfall in Diagnosis.

AJSP Rev Rep. 2022

[6]
Family Matters: Germline Testing in Thoracic Cancers.

Am Soc Clin Oncol Educ Book. 2023-5

[7]
Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.

Diagnostics (Basel). 2023-1-9

[8]
Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.

Medicine (Baltimore). 2022-12-30

[9]
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.

ESMO Open. 2022-12

[10]
A Pilot Mixed-Methods Study of Malignant Pleural Mesothelioma Symptoms.

Oncol Nurs Forum. 2022-10-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索